Search PubMed⌕ Search

Biomedical subjects

M Bloch

Publications and source records attributed to M Bloch.

At least 91 records · Page 5Linked to original sources
PubMed1987

First-trimester prenatal diagnosis for Huntington's disease with DNA probes.

Polymorphic DNA probes linked to the locus for Huntington disease (HD) were used for prenatal diagnosis of a 10-week fetus at 25% risk for the disease. The fetus proved to have a 48% risk of having inherited the HD mutation which was similar to that for the at-risk parent (50%). On this basis the parents elected to terminate the pregnancy. When appropriate family members are available and DNA studies are informative, prenatal diagnosis of HD with polymorphic DNA probes can determine the at-risk status of the fetus with 96% accuracy.

Adult↗
PubMed1986

[Perinatal factors in mucous otitis].

From the retrospective study of 141 children suffering from mucous otitis requiring drainage, the percentage of 40% perinatal factors (birth by cesareans, prematurity, neonatal intensive care) has been found much higher than in the general population. This suggests: 1. that there is, under these conditions, a deficiency of ventilation of the middle ear linked to a pathology of the "surfactant", and/or to a poor resorption of the intra-auricular fluid and mesenchyma of the drum of the ear; 2. that preventive measures should be taken in this high risk population, consisting of systematic ear examinations with pneumo-otoscopy during compulsory health examinations and tympanometry if an abnormality of the ear drum is found.

Child, Preschool↗
PubMed1984

A novel cyclooxygenase metabolite of arachidonic acid.

The 8000 X g pellet of rabbit placenta transformed arachidonic acid into a number of lipoxygenase and cyclooxygenase products of known structure. A metabolite was also produced which was inhibited by indomethacin and required calcium for its formation. This compound had a UV absorption maximum at 227 nm under acidic or neutral conditions and gave a bathochromic shift to 281 nm under alkaline conditions. Reduction of this metabolite with sodium borohydride produced prostaglandin (PG) F2 alpha (as determined by mass spectrometry), while catalytic hydrogenation increased the molecular weight by four mass units, indicating the presence of two double bonds. Based on the mass spectrum of the derivatized metabolite, the structure proved to be 9,15-dioxo-11-hydroxyprosta-5,13-dienoic acid. This compound is produced by the term placenta and does not appear to be formed from PGE2, PGF2 alpha, or PGD2. The compound is suppressed by GSH and NADPH, but its formation is not increased by NAD or NADP. PGH2 and PGG2 are not converted to 9,15-dioxo-11-hydroxyprosta-5,13-dienoic acid under similar in vitro incubation conditions. This therefore represents conversion of arachidonate to 9,15-dioxo-11-hydroxyprosta-5,13-dienoic acid through a Ca2+-dependent, non-PG dehydrogenase pathway.

Animals↗
PubMed1984

Feeding of antigen reduces antigen-binding activity and blunts the secondary response of actively immunized rats.

Enteric administration of soluble or particulate antigens to unprimed animals has been repeatedly demonstrated to blunt or abrogate the cellular and humoral immune response to parenteral immunization. We tested the effect of administering bovine serum albumin by gavage or in the drinking water on the serum antigen-binding activity of rats primed by previous immunization with bovine serum albumin and alum. In some animals, this treatment served initially to boost the systemic humoral response; prolonged treatment led to a reduction in antigen-binding activity at a faster rate than was observed in sham-fed controls. In all rats treated with enteric antigen, the booster response to a second parenteral immunization was reduced or absent. Example of the use of enteric antigen in treatment of patients are cited. On the basis of our findings in rats and those of other investigators who studied mice, as well as the results obtained in patients, it is suggested that further exploration of the enteric approach to treating actively immunized subjects appears warranted.

Administration, Oral↗
PubMed1981

Serologic and parasitologic studies of Entamoeba histolytica in El Salvador, 1974-1978.

Serologic and parasitologic studies were done in El Salvador, C.A., from 1974-1978 to examine the reliability of the diagnosis of Entamoeba histolytica infection in an endemic area and to confirm the estimates of morbidity and mortality due to amebiasis. The results suggest that infection with E. histolytica is common, but the estimated prevalence is too high. Misdiagnosis occurring in hospital and public health laboratories was documented. Data collected from examining family members of persons with E. histolytica infection and disease indicate that most infections are asymptomatic, and support the hypothesis that estimates of morbidity and mortality rates are excessive.

Adolescent↗
PubMed1978

Ketoprofen: double-blind cross-over study with indomethacin administered as a combined suppository/capsule regime in patients with rheumatoid arthritis. A preliminary report.

A double-blind cross-over study is being undertaken in fifty patients with "definite" rheumatoid arthritis, comparing ketoprofen (2-(3-phenylbenzoyl proprionic acid) 75 mg daily orally and 100 mg suppository at night with indomethacin in the same dosage. A pilot study of twenty-four patients has been completed, fifteen having finished the trial. The objective assessment of grip strength and articular index were comparable with the two drugs, but subjective assessment showed that relief of early morning stiffness was better with indomethacin, although pain relief was no different. Evidence so far available shows that ketoprofen is a useful anti-inflammatory analgesic drug which is well tolerated and that the use of a suppository may be helpful in a few patients who find the oral route unacceptable. A larger study is necessary to evaluate finally the use of a combined administration.

Administration, Oral↗
PubMed1973

Double-blind cross-over study of ketoprofen and ibuprofen in management of rheumatoid arthritis.

A double-blind cross-over study of ketoprofen (Orudis) 150 mg daily and ibuprofen (Brufen) 1,200 mg daily was carried out in 35 outpatients with rheumatoid arthritis. Results suggest that analgesic and anti-inflammatory activity of ketoprofen is superior to that of ibuprofen. Significantly greater pain relief (P < 0.05) and reduction in joint circumference (P < 0.01) was obtained with ketoprofen than with ibuprofen. Side effects of the drugs were comparable and not serious.

Acetaminophen↗
PubMed1972

Orudis in management of rheumatoid arthritis and osteoarthrosis of the hip: comparison with indomethacin.

In double-blind cross-over studies in 46 patients with rheumatoid arthritis and in 42 patients with osteoarthrosis of the hip, Orudis-a new non-steroidal anti-inflammatory agent-has been shown to be well tolerated and to have comparable therapeutic efficacy with indomethacin when given in equal dosage. Side effects were less severe with Orudis. The results suggest that Orudis will prove valuable in the clinical management of rheumatic diseases.

Adult↗